Valeant Gains Medicis Through $2.6 Billion Acquisition
This article was originally published in The Gray Sheet
Executive Summary
The deal is mostly pharmaceutical focused, but Medicis sells several injectable dermal filler devices, including Restylane and Perlane.
You may also be interested in...
Nestlé/Galderma Expands U.S. Dermal-Filler Stake As Valeant Raises Bid For Allergan
Swiss dermatology firm Galderma, soon to be a Nestlé subsidiary, will gain access to the Sculptra dermal filler device and a North American sales presence for four other medical aesthetics products in a $1.4 billion sell-off by Valeant intended to strengthen its position to buy Allergan.
Deals Of The Week: Can Endo Succeed By Copying The Valeant Model?
NuPathe and its migraine patch product Zecuity are the latest acquisition by Endo since former Valeant executive Rajiv De Silva moved into the chief executive’s office – will he succeed in bringing his former company’s model to the specialty firm? Plus, Valeant made its own news during the week, while AstraZeneca bought out Bristol’s share of their diabetes joint venture, and more.
Valeant Adds Energy To Its Aesthetics Offerings With Solta Medical
Valeant Pharmaceuticals says it will buy energy-based aesthetics device firm Solta Medical for about $250 million, to expand the breadth of its offerings to dermatologists and plastic surgeons.